Dec 05, 2019
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office
Jun 10, 2019
Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions
Feb 20, 2019
Citrin Cooperman Celebrates 40th Anniversary
Oct 09, 2018
Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
Sep 26, 2018
Metadichol - a Breakthrough in Diabetes Treatment From Nanorx Inc.
Jul 24, 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Jun 08, 2018
New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association's 78th Annual Scientific Sessions
May 24, 2018
New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY
Nov 03, 2017
INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Sep 05, 2017
Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
Jun 12, 2017
INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction, and Stroke in the CANVAS Program
Jun 12, 2017
INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program
Jun 05, 2017
Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions